Proud to be named a Highly Cited Researcher 2019 for significant influence in Clinical Medicine through publication of multiple papers, highly cited by my peers, over the last decade. See the full list of
#HighlyCitedResearchers
2019
@adamfeuerstein
Not sure what journalistic purpose your inflammatory tweet serves, other than, well, to be inflammatory. Physicians and scientists have every right to publish valid findings. My clearly stated disclosures don't change the facts in the paper. Reflect a bit about your own motives.
ACC 2020 live meeting now officially canceled (as I think everyone was expecting). Virtual meeting options to follow - very exciting! Perhaps this crisis will move us as a field towards more innovative, time- and cost-efficient ways of disseminating knowledge.
Cardiovascular risk in the USA: Now we can REDUCE-IT w/ icosapent ethyl, including a statistically significant 30% reduction in all-cause mortality in US patients! REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States | Circulation
See the presentation by Dr.
@benpeterson71
for the striking results from REDUCE-IT REVASC! A 32% reduction in stenting and a 39% reduction in coronary artery bypass surgery - quite remarkable in a blinded, placebo-controlled trial with independent, blinded endpoint adjudication.
Congratulations
@MRMehraMD
on being named the first recipient of the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at
@BrighamWomens
- and a nice touch to have Dr. Braunwald bless your Chair! I am so happy for you and Gayatri and your wonderful family!
Effect of icosapent ethyl on progression of
#coronary
atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
#EHJ
#ESCCongress
#cardiotwitter
A late-stage study showed that Vascepa can reduce the risk of cardiovascular-disease events in patients with elevated triglyceride levels who are high risk and on cholesterol-lowering drugs via
@WSJ
@adamfeuerstein
My job is that I am literally in the hospital on call right now taking care of sick patients. So, no more time to waste receiving your vitriol. At least your Twitter bio was accurate, you do "attack viciously" - glad you are proud of it.
Being presented at
#AHA22
by Sam Sherratt, self-funded work from the lab of Dr. Preston Mason in collaboration with Dr. Peter Libby showing no effect of mineral oil (or corn oil for that matter) on LDL oxidation. It's the EPA.
#cardiology
#cardiotwitter
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials | European Heart Journal | Oxford Academic
SOLOIST in print in
@NEJM
- benefits of SGLT2 inhibition in acute
#HeartFailure
(after initial stabilization). Consistent results in patients with reduced ejection fraction and, for the first time, in preserved ejection fraction!
@gabrielsteg
@cpcannon
Based on the ODYSSEY trial published in
@NEJM
the
@US_FDA
has approved alirocumab to prevent heart attack, stroke, and unstable angina requiring hospitalization. Congratulations
@gabrielsteg
- great development for patients and thanks for involving me in the trial.
@DLBHATTMD
Just flew in from Boston to DC for
@ACCinTouch
Board of Trustees meeting.
@JohnKerry
on flight, so my wife told me to go talk to him. But then on escalator in front of us, girl's shoelace getting sucked into escalator, foot trapped, I broke the shoelace, saved the foot!
I really enjoyed speaking with
@CMichaelGibson
about
#COVID19
- he is not just an expert on the topic, but also a patient! Thanks for sharing your personal story of
#COVID19
illness, self-quarantine, and recovery - many people will benefit.
To understand the truth about EPA and icosapent ethyl, make sure to see our comprehensive supplement available freely online at
@ESC_Journals
. Two independent randomized trials - REDUCE-IT (placebo) and JELIS (no placebo) - prove it works.
#cardiotwitter
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results
#cardiology
#cardiotwitter
Just published in
@NEJM
, a phase 2 trial of the aldosterone synthase inhibitor baxdrostat in resistant
#hypertension
that showed significant reductions in systolic and diastolic blood pressure with the highest dose tested:
Now posted online at
#AHA20
is a very insightful and timely poster from Dr. Preston Mason's lab - Eicosapentaenoic Acid, but Not Docosahexaenoic Acid or a Mixed Omega-3 Fatty Acid Supplement, Inhibits Low-density Lipoprotein Oxidation in a Time-dependent Manner - look for it!
At
#ESCCongress
by
@BudoffMd
- Mechanistic insights into the large benefits in REDUCE-IT: Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Please see attached thoughts from Dr. Wang and myself on how we can learn from this tragedy of COVID-19 and make our healthcare system better. COVID-19: An Unintended Force for Medical Revolution?
Tune in to the encore late breaker for REDUCE-IT REVASC at the American Society of Preventive Cardiology 2020, with new data demonstrating the very early benefits seen with icosapent ethyl. via
@MHExecutive
If you want a quick recap of icosapent ethyl through REDUCE-IT and beyond, here it is! Now in this
@ESC_Journals
supplement. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
#cardiotwitter
#cardiology
@escardio